Healthcare / Drug Manufacturers - Specialty & GenericTSXV
$0.12
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.4M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$69M
P/E
N/A
•EV/EBITDA
16.8x
↑ROE
-4.7%
↓Gross Margin
36.7%
↓Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.4%
FCF CAGR
+7.3%
FCF margin
4.9%
FCF / Net income
-1.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $112.7M · net income $-2.9M · FCF $5.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $112.7M | $112.7M | $92.5M | $106.2M | $79.3M |
| Net Income | $-2.9M | $-2.9M | $9.5M | $-1.8M | $-4.5M |
| EBITDA | $6.3M | $6.3M | $21.5M | $3.2M | $2.3M |
| EPS | -0.01 | -0.01 | 0.02 | -0.00 | -0.01 |
| Gross Margin | 36.7% | 36.7% | 40.6% | 36.5% | 33.3% |
| Operating Margin | 0.3% | 0.3% | 2.8% | 5.1% | -0.4% |
| Net Margin | -2.6% | -2.6% | 10.2% | -1.7% | -5.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.71 | 0.71 | 0.75 | 1.05 | 1.03 |
| Current Ratio | 2.76 | 2.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.5M | $5.5M | $3.0M | $4.4M | $4.4M |
| Returns | |||||
| ROE | -4.7% | -4.7% | 14.6% | -3.8% | -9.5% |
| Valuation | |||||
| P/E | — | — | 3.50 | — | — |
| EV/EBITDA | 16.84 | 16.84 | 3.31 | 31.48 | 39.77 |
| P/B | 1.11 | 1.11 | 0.46 | 1.24 | 0.94 |
| Growth & Yield | |||||
| Revenue Growth | 21.8% | 21.8% | -12.9% | 33.9% | — |
| EPS Growth | -150.0% | -150.0% | 561.1% | 56.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+84.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.02 → -0.01
Residual
+84.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.